{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-002072","form_type":"8-K","ticker":"REPL","cik":"0001737953","company_name":"Replimune Group, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.350200+00:00","generated_at":"2026-06-07T02:24:44.090104+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Replimune reports ~$466M cash, runway into 2H 2026; updates RP1/RP2 clinical data","bullets":["Preliminary cash and equivalents of ~$466M as of Dec 31, 2023; funds operations into second half of 2026.","Updated clinical data for RP1 and RP2 presented at 42nd J.P. Morgan Healthcare Conference.","Cash estimate is unaudited, subject to completion of quarterly closing procedures."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-002072","json":"https://secwatch.observer/filing/0001104659-24-002072.json","markdown":"https://secwatch.observer/filing/0001104659-24-002072.md","text":"https://secwatch.observer/filing/0001104659-24-002072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465924002072/0001104659-24-002072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465924002072/tm242298d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:24:44.090104+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}